Lilly, Novo Nordisk Present Promising Data in Type 2 Diabetes
June 28, 2021 / Diabetes / Pharmaceuticals
Eli Lilly’s investigational diabetes drug is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. All three doses of the investigational drug generated statistically significant results.
Reveal the “Hidden Clinical Leaders” Who Drive HCP Network Adoption
June 28, 2021 / Pharma / Clinical Development / HCPs
Scientific and academic opinion leaders have major impacts on creating initial awareness and establishing treatment narratives, but don’t typically drive product adoption amongst Healthcare Provider communities.
June 23, 2021 Marketing / Pharma / Innovation
Johnson & Johnson is launching a first-ever pair of innovation challenges with military veterans in mind. The initial Quickfire “Veterans Lead” challenge is already underway and crowdsources health solutions from veterans, while the second is set to launch this week and aims to come up with ideas to better serve veterans.
June 23, 2021 / Clinical Development / Digital Innovation
The news: HumanFirst (formerly Elektra Labs), a tech startup focused on building out remote clinical trials, and the Duke Clinical Research Institute (DCRI) are launching the Digital Measures Evaluation Center to assess how biometric sensors and other digital health measures can be best used in clinical trials.
June 28, 2021 / Oncology / Private Equity & Venture Capital
Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors. The financing will support SHINE’s commercialization of its diagnostic and therapeutic medical isotope technologies and position the company for future growth as it works toward developing new fusion-based technology applications.
June 25, 2021 Medical Startups / Innovation / 4IR
“What’s happening in our society? Chronic diseases, chronic pain, diabetes and obesity,” she said. “That doesn’t require a magic pill and there’s not just a surgery. Oftentimes, there’s therapeutic components, behavior changes and movable touch points.” Enter personalized medicine. The buzzy yet powerful framing is growing in popularity among Silicon Valley startups.
June 26, 2021 / CRISPR / Innovation / Gene Therapies
The gene editor CRISPR excels at fixing disease mutations in lab-grown cells. But using CRISPR to treat most people with genetic disorders requires clearing an enormous hurdle: getting the molecular scissors into the body and having it slice DNA in the tissues where it’s needed.
June 28, 2021 / Obesity / Preclinical Research
A protein called Them1 prevents fat burning in cells by blocking access to the fuel source, according to preclinical research by Weill Cornell Medicine/NewYork-Presbyterian and Harvard Medical School/Beth Israel Deaconess Medical Center investigators. The findings may contribute to the development of a new type of obesity treatment that targets this response.
June 28, 2021 / Diabetes / Clinical Development
Data released today from a large-scale, international clinical trial show significant reduction in the first occurrence of a heart attack, stroke, or death, and a reduction in progression of kidney disease in patients with type 2 diabetes with weekly use of efpeglenatide, an injectable drug with glucose- and weight-lowering effects.
June 28, 2021 / Neurology / Alzheimer’s / Pharmaceuticals
Despite unproven efficacy, Biogen set the drug’s list price at $56,000 per year. Concern is mounting over the price of the controversial new Alzheimer’s drug Aduhelm. Advocates, lawmakers, and critics worry in particular about what the drug’s $56,000 per-year list price will do to Medicare.